Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CASP3 | P42574 | 3/20 | 0.43 |
| ▸ | GZMB | P10144 | 3/20 | 0.39 |
| ▸ | CASP1 | P29466 | 6/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | THRB | P10828 | 1/20 | 0.38 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.38 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.38 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.38 |
| ▸ | THPO | P40225 | 1/20 | 0.38 |
| ▸ | RECQL | P46063 | 1/20 | 0.38 |
| ▸ | BLM | P54132 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | GNPAT | O15228 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8360127 | 1.00 | CASP3 (0.43) | CASP3GZMBCASP1KDM4EMAPT | |
| SCHEMBL4599055 | 1.00 | CASP3 (0.43) | CASP3GZMBCASP1KDM4EMAPT | |
| SCHEMBL7275397 | 0.85 | CASP1 (0.41) | CASP3GZMBCASP1 | |
| SCHEMBL23288380 | 0.84 | ALDH1A1 (0.39) | CASP3GZMBKDM4EMAPTTHRB | |
| SCHEMBL5454579 | 0.81 | KDM4E (0.32) | KDM4EMAPTTHRBALOX15NFKB1 | |
| SCHEMBL11557965 | 0.81 | KDM4E (0.32) | KDM4EMAPTTHRBALOX15NFKB1 | |
| SCHEMBL12809931 | 0.81 | CASP3 (0.45) | CASP3GZMBCASP1 | |
| SCHEMBL7275500 | 0.81 | CASP3 (0.45) | CASP3GZMBCASP1 | |
| SCHEMBL200456 | 0.79 | PLA2G2C (0.40) | — | |
| SCHEMBL24809460 | 0.79 | PLA2G2C (0.40) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1910309-A2 | CYCLOALKYL AMINO-HYDANTOIN COMPOUNDS AND USE THEREOF FOR ß-SECRETASE MODULATION | Wyeth (US) | 2008-04-16 | — | — | EP | disclosed |
| WO-2007016012-A2 | CYCLOALKYL AMINO-HYDANTOIN COMPOUNDS AND USE THEREOF FOR β-SECRETASE MODULATION | WYETH (US) | 2007-02-08 | — | — | WO | disclosed |
| US-20070027199-A1 | Cycloalkyl amino-hydantoin compounds and use thereof for beta-secretase modulation | WYETH (US) | 2007-02-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070027199-A1 | Cycloalkyl amino-hydantoin compounds and use thereof for beta-secretase modulation | BACE1, BACE2, APP | CASP3 101/4885GZMB 2500/4885CASP1 100/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.